DK1066376T3 - Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner - Google Patents

Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner

Info

Publication number
DK1066376T3
DK1066376T3 DK99911949T DK99911949T DK1066376T3 DK 1066376 T3 DK1066376 T3 DK 1066376T3 DK 99911949 T DK99911949 T DK 99911949T DK 99911949 T DK99911949 T DK 99911949T DK 1066376 T3 DK1066376 T3 DK 1066376T3
Authority
DK
Denmark
Prior art keywords
ompf
aroc
mutation
vaccines
reversing
Prior art date
Application number
DK99911949T
Other languages
Danish (da)
English (en)
Inventor
Steven Neville Chatfield
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of DK1066376T3 publication Critical patent/DK1066376T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK99911949T 1998-03-25 1999-03-25 Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner DK1066376T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
EP99911949A EP1066376B1 (de) 1998-03-25 1999-03-25 Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff

Publications (1)

Publication Number Publication Date
DK1066376T3 true DK1066376T3 (da) 2005-10-03

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99911949T DK1066376T3 (da) 1998-03-25 1999-03-25 Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner

Country Status (19)

Country Link
US (1) US6902906B1 (de)
EP (1) EP1066376B1 (de)
JP (1) JP4516210B2 (de)
KR (1) KR100628657B1 (de)
AT (1) ATE296881T1 (de)
AU (1) AU763683B2 (de)
CA (1) CA2323576C (de)
CZ (1) CZ301520B6 (de)
DE (1) DE69925585T2 (de)
DK (1) DK1066376T3 (de)
ES (1) ES2244182T3 (de)
GB (1) GB9806449D0 (de)
HU (1) HU225644B1 (de)
NO (1) NO327609B1 (de)
NZ (1) NZ507077A (de)
PL (1) PL196076B1 (de)
PT (1) PT1066376E (de)
WO (1) WO1999049026A1 (de)
ZA (1) ZA200004987B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
WO2002057780A1 (en) * 2001-01-18 2002-07-25 Newcastle University Ventures Ltd. Biosensor with covalently attached membrane-spanning proteins
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
EP2857038B1 (de) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
NO2525817T3 (de) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
WO2014037445A1 (en) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Preparation of live vaccines
CN104995292A (zh) 2012-12-07 2015-10-21 洛曼动物健康有限责任公司 活疫苗制备
EP2956165B1 (de) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen gegenüber eimeria oder zur begrenzung von eimeria-infektionen
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE111957T1 (de) * 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
ATE180280T1 (de) * 1991-03-05 1999-06-15 Wellcome Found Expression rekombinanter proteine in attenuierten bakterien

Also Published As

Publication number Publication date
AU763683B2 (en) 2003-07-31
EP1066376A1 (de) 2001-01-10
JP4516210B2 (ja) 2010-08-04
PT1066376E (pt) 2005-10-31
HUP0105430A2 (hu) 2002-04-29
NZ507077A (en) 2002-10-25
CA2323576A1 (en) 1999-09-30
JP2002507414A (ja) 2002-03-12
HU225644B1 (en) 2007-05-02
DE69925585D1 (de) 2005-07-07
PL343246A1 (en) 2001-07-30
CA2323576C (en) 2010-12-07
PL196076B1 (pl) 2007-12-31
ATE296881T1 (de) 2005-06-15
NO20004781L (no) 2000-11-08
KR100628657B1 (ko) 2006-09-26
KR20010042175A (ko) 2001-05-25
ZA200004987B (en) 2001-10-31
CZ20003470A3 (cs) 2001-07-11
DE69925585T2 (de) 2006-07-13
WO1999049026A1 (en) 1999-09-30
ES2244182T3 (es) 2005-12-01
HUP0105430A3 (en) 2004-10-28
US6902906B1 (en) 2005-06-07
NO327609B1 (no) 2009-08-31
GB9806449D0 (en) 1998-05-27
EP1066376B1 (de) 2005-06-01
AU3045899A (en) 1999-10-18
NO20004781D0 (no) 2000-09-25
CZ301520B6 (cs) 2010-03-31

Similar Documents

Publication Publication Date Title
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
Brown et al. MlrA, a novel regulator of curli (AgF) and extracellular matrix synthesis by Escherichia coli and Salmonella enterica serovar Typhimurium
Oyston et al. The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis
Pukatzki et al. Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system
Balsanelli et al. Herbaspirillum seropedicae rfbB and rfbC genes are required for maize colonization
Abu Kwaik et al. Invasion of protozoa by Legionella pneumophila and its role in bacterial ecology and pathogenesis
Atkins et al. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis
KR937000640A (ko) 생 백신
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
Yamashita et al. Genes involved in cell wall localization and side chain formation of rhamnose-glucose polysaccharide in Streptococcus mutans
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
Zogaj et al. Characterization of the Francisella tularensis subsp. novicida type IV pilus
Shrivastava et al. A Schiff base complex of chromium (III): an efficient inhibitor for the pathogenic and invasive potential of Shigella dysenteriae
ATE308991T1 (de) Bakterieller impfstoff
DE60226175D1 (de) Mycobakterieller impfstoff
DE60136563D1 (de) Salmonella vakzine
Gunn et al. Constitutive mutations of the Salmonella enterica serovar Typhimurium transcriptional virulence regulator phoP
FI102078B1 (fi) Alkoholeja lohkaisemalla elastomeereiksi verkkoutettavat organo(poly)siloksaanimassat
EA200600121A1 (ru) Безопасные мутантные вирусные вакцины
WO2000003003A3 (en) Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
Meyer et al. Virulence of a Salmonella typhimurium OmpD mutant
Seshadri et al. Genome analysis of Coxiella burnetii species: insights into pathogenesis and evolution and implications for biodefense
Li et al. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococci
Krueger et al. Unravelling post‐transcriptional PrmC‐dependent regulatory mechanisms in Pseudomonas aeruginosa
GT200000138CA (es) Gen de steptomyces avermitilis que dirige la relacion de avermectinas b1:b2 (solicitud fraccionaria no.3, derivada de lapatente pi-2000-0138)